Stephen J. Freedland, MD

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

Stephen J. Freedland, MD, discussed an analysis real-world patients with metastatic castration-resistant prostate cancer, which he presented at the 2020 Genitourinary Cancers Symposium.

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index and prostate cancer risk.